ME Therapeutics Holdings Inc., a biotechnology company focused on immuno-oncology, has commenced efficacy testing of its initial mRNA formulations in collaboration with NanoVation Therapeutics Inc. The partnership leverages NanoVation's lipid nanoparticle (LNP) technologies to enhance the precision and efficacy of myeloid cell-delivered mRNA therapeutics for potential cancer treatments.
Strategic Collaboration and Technology
The collaboration between ME Therapeutics and NanoVation Therapeutics aims to exploit NanoVation's next-generation lipid nanoparticle platforms, which are engineered for efficient nucleic acid delivery to various tissues. NanoVation's long-circulating LNP (lcLNP) technology is specifically designed to target immune cells, optimizing its delivery for therapeutic effect. This technology underpins multiple RNA modality programs.
CEO's Perspective
Salim Dhanji, chief executive officer of ME Therapeutics, emphasized the speed of development, stating, "The speed at which we were able to go from announcing our research collaboration to having a testable drug demonstrates the potential of mRNA as a rapidly developable therapeutic modality to potentially treat cancer and other diseases." He further added, "These initial studies will increase our understanding of the therapeutic potential of mRNA delivery to myeloid cells for the treatment of cancer."
Myeloid Enhancement Therapeutics Focus
ME Therapeutics, based in Vancouver, is dedicated to discovering and developing novel immuno-oncology therapeutics. The company's primary focus is on counteracting the suppressive effects of myeloid cells to bolster anti-cancer immunity.
